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DEFINITION AND
DESCRIPTION OF DIABETES
MELLITUS— Diabetes mellitus is a
group of metabolic diseases characterized
by hyperglycemia resulting from defects
in insulin secretion, insulin action, or
both. The chronic hyperglycemia of dia-
betes is associated with long-term dam-
age, dysfunction, and failure of various
organs, especially the eyes, kidneys,
nerves, heart, and blood vessels.
Several pathogenic processes are in-
volved in the development of diabetes.
These range from autoimmune destruc-
tion of the -cells of the pancreas with
consequent insulin deﬁciency to abnor-
malities that result in resistance to insulin
action. The basis of the abnormalities in
carbohydrate, fat, and protein metabo-
lism in diabetes is deﬁcient action of in-
sulin on target tissues. Deﬁcient insulin
action results from inadequate insulin se-
cretion and/or diminished tissue re-
sponsestoinsulinatoneormorepointsin
thecomplexpathwaysofhormoneaction.
Impairment of insulin secretion and de-
fects in insulin action frequently coexist
in the same patient, and it is often unclear
which abnormality, if either alone, is the
primary cause of the hyperglycemia.
Symptoms of marked hyperglycemia
include polyuria, polydipsia, weight loss,
sometimes with polyphagia, and blurred
vision.Impairmentofgrowthandsuscep-
tibility to certain infections may also ac-
company chronic hyperglycemia. Acute,
life-threatening consequences of uncon-
trolled diabetes are hyperglycemia with
ketoacidosis or the nonketotic hyperos-
molar syndrome.
Long-term complications of diabetes
include retinopathy with potential loss of
vision;nephropathyleadingtorenalfailure;
peripheral neuropathy with risk of foot ul-
cers, amputations, and Charcot joints; and
autonomicneuropathycausinggastrointes-
tinal, genitourinary, and cardiovascular
symptoms and sexual dysfunction. Patients
with diabetes have an increased incidence
of atherosclerotic cardiovascular, periph-
eral arterial, and cerebrovascular disease.
Hypertensionandabnormalitiesoflipopro-
tein metabolism are often found in people
with diabetes.
The vast majority of cases of diabetes
fall into two broad etiopathogenetic cate-
gories (discussed in greater detail below).
Inonecategory,type1diabetes,thecause
is an absolute deﬁciency of insulin secre-
tion. Individuals at increased risk of de-
velopingthistypeofdiabetescanoftenbe
identiﬁed by serological evidence of an
autoimmune pathologic process occur-
ringinthepancreaticisletsandbygenetic
markers. In the other, much more preva-
lent category, type 2 diabetes, the cause is
a combination of resistance to insulin ac-
tion and an inadequate compensatory in-
sulin secretory response. In the latter
category, a degree of hyperglycemia sufﬁ-
cient to cause pathologic and functional
changes in various target tissues, but
without clinical symptoms, may be
present for a long period of time before
diabetes is detected. During this asymp-
tomatic period, it is possible to demon-
strate an abnormality in carbohydrate
metabolism by measurement of plasma
glucose in the fasting state or after a chal-
lenge with an oral glucose load.
The degree of hyperglycemia (if any)
may change over time, depending on the
extent of the underlying disease process
(Fig. 1). A disease process may be present
but may not have progressed far enough
tocausehyperglycemia.Thesamedisease
process can cause impaired fasting glu-
cose (IFG) and/or impaired glucose toler-
ance (IGT) without fulﬁlling the criteria
for the diagnosis of diabetes. In some in-
dividuals with diabetes, adequate glyce-
mic control can be achieved with weight
reduction, exercise, and/or oral glucose-
lowering agents. These individuals there-
fore do not require insulin. Other
individuals who have some residual insu-
lin secretion but require exogenous insu-
lin for adequate glycemic control can
survive without it. Individuals with ex-
tensive -cell destruction and therefore
noresidualinsulinsecretionrequireinsu-
lin for survival. The severity of the meta-
bolic abnormality can progress, regress,
or stay the same. Thus, the degree of hy-
perglycemiareﬂectstheseverityoftheun-
derlying metabolic process and its
treatment more than the nature of the
process itself.
CLASSIFICATION OF
DIABETES MELLITUS AND
OTHER CATEGORIES OF
GLUCOSE REGULATION—
Assigning a type of diabetes to an individ-
ual often depends on the circumstances
presentatthetimeofdiagnosis,andmany
diabeticindividualsdonoteasilyﬁtintoa
single class. For example, a person with
gestational diabetes mellitus (GDM) may
continue to be hyperglycemic after deliv-
ery and may be determined to have, in
fact, type 2 diabetes. Alternatively, a per-
son who acquires diabetes because of
largedosesofexogenoussteroidsmaybe-
come normoglycemic once the glucocor-
ticoids are discontinued, but then may
developdiabetesmanyyearslaterafterre-
current episodes of pancreatitis. Another
example would be a person treated with
thiazides who develops diabetes years
later. Because thiazides in themselves sel-
domcauseseverehyperglycemia,suchin-
dividuals probably have type 2 diabetes
that is exacerbated by the drug. Thus, for
theclinicianandpatient,itislessimportant
tolabeltheparticulartypeofdiabetesthanit
istounderstandthepathogenesisofthehy-
perglycemia and to treat it effectively.
Type 1 diabetes (-cell destruction,
usually leading to absolute insulin
deﬁciency)
Immune-mediated diabetes. This form
of diabetes, which accounts for only
5–10% of those with diabetes, previously
encompassed by the terms insulin-
dependentdiabetes,typeIdiabetes,orju-
venile-onset diabetes, results from a
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tion of the -cells of the pancreas. Mark-
ers of the immune destruction of the
-cell include islet cell autoantibodies,
autoantibodies to insulin, autoantibodies
to glutamic acid decarboxylase (GAD65),
and autoantibodies to the tyrosine phos-
phatasesIA-2andIA-2.Oneandusually
more of these autoantibodies are present
in 85–90% of individuals when fasting
hyperglycemia is initially detected. Also,
the disease has strong HLA associations,
with linkage to the DQA and DQB genes,
and it is inﬂuenced by the DRB genes.
These HLA-DR/DQ alleles can be either
predisposing or protective.
In this form of diabetes, the rate of
-cell destruction is quite variable, being
rapid in some individuals (mainly infants
and children) and slow in others (mainly
adults). Some patients, particularly chil-
dren and adolescents, may present with
ketoacidosis as the ﬁrst manifestation of
the disease. Others have modest fasting
hyperglycemia that can rapidly change to
severehyperglycemiaand/orketoacidosis
inthepresenceofinfectionorotherstress.
Stillothers,particularlyadults,mayretain
residual -cell function sufﬁcient to pre-
ventketoacidosisformanyyears;suchin-
dividuals eventually become dependent
on insulin for survival and are at risk for
ketoacidosis.Atthislatterstageofthedis-
ease, there is little or no insulin secretion,
as manifested by low or undetectable lev-
els of plasma C-peptide. Immune-
mediated diabetes commonly occurs in
childhood and adolescence, but it can oc-
cur at any age, even in the 8th and 9th
decades of life.
Autoimmune destruction of -cells
has multiple genetic predispositions and
is also related to environmental factors
that are still poorly deﬁned. Although pa-
tients are rarely obese when they present
with this type of diabetes, the presence of
obesity is not incompatible with the diag-
nosis. These patients are also prone to
other autoimmune disorders such as
Graves’ disease, Hashimoto’s thyroiditis,
Addison’s disease, vitiligo, celiac sprue,
autoimmunehepatitis,myastheniagravis,
and pernicious anemia.
Idiopathicdiabetes. Someformsoftype
1 diabetes have no known etiologies.
Some of these patients have permanent
insulinopeniaandarepronetoketoacido-
sis, but have no evidence of autoimmu-
nity. Although only a minority of patients
withtype1diabetesfallintothiscategory,
of those who do, most are of African or
Asianancestry.Individualswiththisform
of diabetes suffer from episodic ketoaci-
dosis and exhibit varying degrees of insu-
lin deﬁciency between episodes. This
form of diabetes is strongly inherited,
lacks immunological evidence for -cell
autoimmunity,andisnotHLAassociated.
An absolute requirement for insulin re-
placement therapy in affected patients
may come and go.
Type 2 diabetes (ranging from
predominantly insulin resistance
with relative insulin deﬁciency to
predominantly an insulin secretory
defect with insulin resistance)
This form of diabetes, which accounts for
90–95% of those with diabetes, previ-
ously referred to as non-insulin-
dependent diabetes, type II diabetes, or
adult-onset diabetes, encompasses indi-
viduals who have insulin resistance and
usually have relative (rather than abso-
lute) insulin deﬁciency At least initially,
and often throughout their lifetime, these
individuals do not need insulin treatment
to survive. There are probably many dif-
ferent causes of this form of diabetes. Al-
though the speciﬁc etiologies are not
known, autoimmune destruction of
-cells does not occur, and patients do
not have any of the other causes of diabe-
tes listed above or below.
Most patients with this form of diabe-
tes are obese, and obesity itself causes
somedegreeofinsulinresistance.Patients
who are not obese by traditional weight
criteria may have an increased percentage
of body fat distributed predominantly in
the abdominal region. Ketoacidosis sel-
dom occurs spontaneously in this type of
diabetes; when seen, it usually arises in
association with the stress of another ill-
Figure 1—Disorders of glycemia: etiologic types and stages. Even after presenting in ketoacidosis, these patients can brieﬂy return to normogly-
cemiawithoutrequiringcontinuoustherapy(i.e.,“honeymoon”remission);inrareinstances,patientsinthesecategories(e.g.,Vacortoxicity,type
1 diabetes presenting in pregnancy) may require insulin for survival.
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betes frequently goes undiagnosed for
many years because the hyperglycemia
develops gradually and at earlier stages is
often not severe enough for the patient to
notice any of the classic symptoms of di-
abetes. Nevertheless, such patients are at
increased risk of developing macrovascu-
lar and microvascular complications.
Whereas patients with this form of diabe-
tes may have insulin levels that appear
normal or elevated, the higher blood glu-
cose levels in these diabetic patients
would be expected to result in even
higher insulin values had their -cell
function been normal. Thus, insulin se-
cretion is defective in these patients and
insufﬁcient to compensate for insulin re-
sistance. Insulin resistance may improve
with weight reduction and/or pharmaco-
logical treatment of hyperglycemia but is
seldom restored to normal. The risk of
developingthisformofdiabetesincreases
with age, obesity, and lack of physical ac-
tivity. It occurs more frequently in
women with prior GDM and in individu-
als with hypertension or dyslipidemia,
anditsfrequencyvariesindifferentracial/
ethnic subgroups. It is often associated
with a strong genetic predisposition,
more so than is the autoimmune form of
type 1 diabetes. However, the genetics of
this form of diabetes are complex and not
clearly deﬁned.
Other speciﬁc types of diabetes
Genetic defects of the -cell. Several
forms of diabetes are associated with mo-
nogenetic defects in -cell function.
These forms of diabetes are frequently
characterized by onset of hyperglycemia
at an early age (generally before age 25
years). They are referred to as maturity-
onset diabetes of the young (MODY) and
are characterized by impaired insulin se-
cretion with minimal or no defects in in-
sulin action. They are inherited in an
autosomal dominant pattern. Abnormali-
ties at six genetic loci on different chro-
mosomes have been identiﬁed to date.
The most common form is associated
with mutations on chromosome 12 in a
hepatic transcription factor referred to as
hepatocyte nuclear factor (HNF)-1.A
second form is associated with mutations
in the glucokinase gene on chromosome
7p and results in a defective glucokinase
molecule. Glucokinase converts glucose
to glucose-6-phosphate, the metabolism
ofwhich,inturn,stimulatesinsulinsecre-
t i o nb yt h e-cell. Thus, glucokinase
serves as the “glucose sensor” for the
-cell. Because of defects in the glucoki-
nase gene, increased plasma levels of glu-
cose are necessary to elicit normal levels
of insulin secretion. The less common
formsresultfrommutationsinothertran-
scription factors, including HNF-4,
HNF-1,insulinpromoterfactor(IPF)-1,
and NeuroD1.
Point mutations in mitochondrial
DNA have been found to be associated
with diabetes mellitus and deafness The
most common mutation occurs at posi-
tion 3243 in the tRNA leucine gene, lead-
ing to an A-to-G transition. An identical
lesion occurs in the MELAS syndrome
(mitochondrial myopathy, encephalopa-
thy, lactic acidosis, and stroke-like syn-
drome); however, diabetes is not part of
this syndrome, suggesting different phe-
notypic expressions of this genetic lesion.
Genetic abnormalities that result in
the inability to convert proinsulin to in-
sulin have been identiﬁed in a few fami-
lies, and such traits are inherited in an
autosomal dominant pattern. The result-
ant glucose intolerance is mild. Similarly,
the production of mutant insulin mole-
cules with resultant impaired receptor
binding has also been identiﬁed in a few
families and is associated with an autoso-
mal inheritance and only mildly impaired
or even normal glucose metabolism.
Genetic defects in insulin action.
There are unusual causes of diabetes that
resultfromgeneticallydeterminedabnor-
malities of insulin action. The metabolic
abnormalities associated with mutations
of the insulin receptor may range from
hyperinsulinemia and modest hypergly-
cemia to severe diabetes. Some individu-
als with these mutations may have
acanthosis nigricans. Women may be vir-
ilizedandhaveenlarged,cysticovaries.In
thepast,thissyndromewastermedtypeA
insulin resistance. Leprechaunism and
the Rabson-Mendenhall syndrome are
two pediatric syndromes that have muta-
tions in the insulin receptor gene with
subsequent alterations in insulin receptor
function and extreme insulin resistance.
The former has characteristic facial fea-
tures and is usually fatal in infancy, while
the latter is associated with abnormalities
of teeth and nails and pineal gland
hyperplasia.
Alterations in the structure and func-
tion of the insulin receptor cannot be
demonstrated in patients with insulin-
resistantlipoatrophicdiabetes.Therefore,
itisassumedthatthelesion(s)mustreside
in the postreceptor signal transduction
pathways.
Diseasesoftheexocrinepancreas. Any
processthatdiffuselyinjuresthepancreas
can cause diabetes. Acquired processes
include pancreatitis, trauma, infection,
pancreatectomy, and pancreatic carci-
noma. With the exception of that caused
by cancer, damage to the pancreas must
be extensive for diabetes to occur; adre-
nocarcinomas that involve only a small
portion of the pancreas have been associ-
ated with diabetes. This implies a mecha-
nism other than simple reduction in
-cell mass. If extensive enough, cystic
ﬁbrosis and hemochromatosis will also
damage -cells and impair insulin secre-
tion. Fibrocalculous pancreatopathy may
be accompanied by abdominal pain radi-
ating to the back and pancreatic calciﬁca-
tions identiﬁed on X-ray examination.
Pancreatic ﬁbrosis and calcium stones in
the exocrine ducts have been found at
autopsy.
Endocrinopathies. Several hormones
(e.g., growth hormone, cortisol, gluca-
gon, epinephrine) antagonize insulin ac-
tion. Excess amounts of these hormones
(e.g., acromegaly, Cushing’s syndrome,
glucagonoma, pheochromocytoma, re-
spectively) can cause diabetes. This gen-
erally occurs in individuals with
preexisting defects in insulin secretion,
and hyperglycemia typically resolves
when the hormone excess is resolved.
Somatostatinoma- and aldoster-
onoma-induced hypokalemia can cause
diabetes, at least in part, by inhibiting in-
sulin secretion. Hyperglycemia generally
resolvesaftersuccessfulremovalofthetu-
mor.
Drug- or chemical-induced diabetes.
Many drugs can impair insulin secretion.
These drugs may not cause diabetes by
themselves, but they may precipitate dia-
betes in individuals with insulin resis-
tance. In such cases, the classiﬁcation is
unclear because the sequence or relative
importance of -cell dysfunction and in-
sulin resistance is unknown. Certain tox-
ins such as Vacor (a rat poison) and
intravenous pentamidine can perma-
nently destroy pancreatic -cells. Such
drug reactions fortunately are rare. There
are also many drugs and hormones that
can impair insulin action. Examples in-
clude nicotinic acid and glucocorticoids.
Patients receiving -interferon have been
reported to develop diabetes associated
with islet cell antibodies and, in certain
instances, severe insulin deﬁciency. The
list shown in Table 1 is not all-inclusive,
but reﬂects the more commonly recog-
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forms of diabetes.
Infections. Certainviruseshavebeenas-
sociated with -cell destruction. Diabetes
occursinpatientswithcongenitalrubella,
although most of these patients have HLA
and immune markers characteristic of
type 1 diabetes. In addition, coxsackievi-
rus B, cytomegalovirus, adenovirus, and
mumps have been implicated in inducing
certain cases of the disease.
Uncommon forms of immune-medi-
ated diabetes. In this category, there are
two known conditions, and others are
likely to occur. The stiff-man syndrome is
an autoimmune disorder of the central
nervous system characterized by stiffness
of the axial muscles with painful spasms.
Patients usually have high titers of the
GAD autoantibodies, and approximately
one-third will develop diabetes.
Anti–insulin receptor antibodies can
cause diabetes by binding to the insulin
receptor, thereby blocking the binding of
insulin to its receptor in target tissues.
However, in some cases, these antibodies
can act as an insulin agonist after binding
to the receptor and can thereby cause hy-
poglycemia. Anti–insulin receptor anti-
bodies are occasionally found in patients
with systemic lupus erythematosus and
other autoimmune diseases. As in other
states of extreme insulin resistance, pa-
tients with anti–insulin receptor antibod-
ies often have acanthosis nigricans. In the
past, this syndrome was termed type B
insulin resistance.
Other genetic syndromes sometimes
associated with diabetes. Many genetic
syndromes are accompanied by an in-
creased incidence of diabetes mellitus.
These include the chromosomal abnor-
malities of Down’s syndrome,
Klinefelter’s syndrome, and Turner’s syn-
drome.Wolfram’ssyndromeisanautoso-
mal recessive disorder characterized by
insulin-deﬁcientdiabetesandtheabsence
of -cells at autopsy. Additional manifes-
tations include diabetes insipidus, hypo-
gonadism, optic atrophy, and neural
deafness. Other syndromes are listed in
Table 1.
Gestational diabetes mellitus (GDM)
GDM is deﬁned as any degree of glucose
intolerance with onset or ﬁrst recognition
during pregnancy. The deﬁnition applies
regardless of whether insulin or only diet
modiﬁcation is used for treatment or
whether the condition persists after preg-
nancy. It does not exclude the possibility
that unrecognized glucose intolerance may
Table 1—Etiologic classiﬁcation of diabetes mellitus
I. Type 1 diabetes (-cell destruction, usually leading to absolute insulin deﬁciency)
A. Immune mediated
B. Idiopathic
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deﬁciency to a
predominantly secretory defect with insulin resistance)
III. Other speciﬁc types
A. Genetic defects of -cell function
1. Chromosome 12, HNF-1 (MODY3)
2. Chromosome 7, glucokinase (MODY2)
3. Chromosome 20, HNF-4 (MODY1)
4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4)
5. Chromosome 17, HNF-1 (MODY5)
6. Chromosome 2, NeuroD1 (MODY6)
7. Mitochondrial DNA
8. Others
B. Genetic defects in insulin action
1. Type A insulin resistance
2. Leprechaunism
3. Rabson-Mendenhall syndrome
4. Lipoatrophic diabetes
5. Others
C. Diseases of the exocrine pancreas
1. Pancreatitis
2. Trauma/pancreatectomy
3. Neoplasia
4. Cystic ﬁbrosis
5. Hemochromatosis
6. Fibrocalculous pancreatopathy
7. Others
D. Endocrinopathies
1. Acromegaly
2. Cushing’s syndrome
3. Glucagonoma
4. Pheochromocytoma
5. Hyperthyroidism
6. Somatostatinoma
7. Aldosteronoma
8. Others
E. Drug- or chemical-induced
1. Vacor
2. Pentamidine
3. Nicotinic acid
4. Glucocorticoids
5. Thyroid hormone
6. Diazoxide
7. -adrenergic agonists
8. Thiazides
9. Dilantin
10. -Interferon
11. Others
F. Infections
1. Congenital rubella
2. Cytomegalovirus
3. Others
G. Uncommon forms of immune-mediated diabetes
1. “Stiff-man” syndrome
2. Anti–insulin receptor antibodies
3. Others
H. Other genetic syndromes sometimes associated with diabetes
1. Down’s syndrome
2. Klinefelter’s syndrome
3. Turner’s syndrome
4. Wolfram’s syndrome
5. Friedreich’s ataxia
6. Huntington’s chorea
7. Laurence-Moon-Biedl syndrome
8. Myotonic dystrophy
9. Porphyria
10. Prader-Willi syndrome
11. Others
IV. Gestational diabetes mellitus (GDM)
Patients with any form of diabetes may require insulin treatment at some stage of their disease. Such use of
insulin does not, of itself, classify the patient.
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with the pregnancy. GDM complicates
4% of all pregnancies in the U.S., result-
ing in 135,000 cases annually. The prev-
alence may range from 1 to 14% of
pregnancies, depending on the population
studied. GDM represents nearly 90% of all
pregnancies complicated by diabetes.
Deterioration of glucose tolerance oc-
curs normally during pregnancy, particu-
larly in the 3rd trimester.
Impaired glucose tolerance (IGT)
and impaired fasting glucose (IFG)
The Expert Committee (1,2) recognized
an intermediate group of subjects whose
glucose levels, although not meeting cri-
teria for diabetes, are nevertheless too
high to be considered normal. This group
is deﬁned as having fasting plasma glu-
cose (FPG) levels 100 mg/dl (5.6
mmol/l) but 126 mg/dl (7.0 mmol/l) or
2-h values in the oral glucose tolerance
test (OGTT) of 140 mg/dl (7.8 mmol/l)
but200mg/dl(11.1mmol/l).Thus,the
categories of FPG values are as follows:
● FPG 100 mg/dl (5.6 mmol/l)  nor-
mal fasting glucose;
● FPG 100–125 mg/dl (5.6–6.9 mmol/
l)  IFG (impaired fasting glucose);
● FPG 126 mg/dl (7.0 mmol/l)  pro-
visional diagnosis of diabetes (the diag-
nosis must be conﬁrmed, as described
below).
The corresponding categories when the
OGTT is used are the following:
● 2-h postload glucose 140 mg/dl (7.8
mmol/l)  normal glucose tolerance;
● 2-h postload glucose 140–199 mg/dl
(7.8–11.1 mmol/l)  IGT (impaired
glucose tolerance);
● 2-hpostloadglucose200mg/dl(11.1
mmol/l)  provisional diagnosis of di-
abetes (the diagnosis must be con-
ﬁrmed, as described below).
PatientswithIFGand/orIGTarenow
referred to as having “pre-diabetes” indi-
cating the relatively high risk for develop-
ment of diabetes in these patients. In the
absence of pregnancy, IFG and IGT are
not clinical entities in their own right but
rather risk factors for future diabetes as
well as cardiovascular disease. They can
be observed as intermediate stages in any
of the disease processes listed in Table 1.
IFG and IGT are associated with the met-
abolic syndrome, which includes obesity
(especiallyabdominalorvisceralobesity),
dyslipidemia of the high-triglyceride
and/or low-HDL type, and hypertension.
Itisworthmentioningthatmedicalnutri-
tion therapy aimed at producing 5–10%
loss of body weight, exercise, and certain
pharmacological agents have been vari-
ablydemonstratedtopreventordelaythe
development of diabetes in people with
IGT; the potential impact of such inter-
ventionstoreducecardiovascularriskhas
not been examined to date.
Note that many individuals with IGT
are euglycemic in their daily lives. Indi-
vidualswithIFGorIGTmayhavenormal
or near normal glycated hemoglobin lev-
els. Individuals with IGT often manifest
hyperglycemia only when challenged
with the oral glucose load used in the
standardized OGTT.
DIAGNOSTIC CRITERIA FOR
DIABETES MELLITUS— The cri-
teria for the diagnosis of diabetes are
showninTable2.Threewaystodiagnose
diabetes are possible, and each, in the ab-
sence of unequivocal hyperglycemia,
must be conﬁrmed, on a subsequent day,
by any one of the three methods given in
Table 2. The use of the hemoglobin A1c
(A1C) for the diagnosis of diabetes is not
recommended at this time.
Diagnosis of GDM
The criteria for abnormal glucose toler-
ance in pregnancy are those of Carpenter
and Coustan (3). Recommendations from
the American Diabetes Association’s
Fourth International Workshop-
Conference on Gestational Diabetes Mel-
litus held in March 1997 support the use
of the Carpenter/Coustan diagnostic cri-
teria as well as the alternative use of a di-
agnostic 75-g 2-h OGTT. These criteria
are summarized below.
Testing for gestational diabetes. Previ-
ousrecommendationsincludedscreening
for GDM performed in all pregnancies.
However, there are certain factors that
place women at lower risk for the devel-
opment of glucose intolerance during
pregnancy, and it is likely not cost-
effectivetoscreensuchpatients.Pregnant
women who fulﬁll all of these criteria
need not be screened for GDM.
This low-risk group comprises
women who
● are 25 years of age
● are a normal body weight
● have no family history (i.e., ﬁrst-degree
relative) of diabetes
● have no history of abnormal glucose
metabolism
● have no history of poor obstetric out-
come
● are not members of an ethnic/racial
group with a high prevalence of diabe-
tes (e.g., Hispanic American, Native
American, Asian American, African
American, Paciﬁc Islander)
Risk assessment for GDM should be
undertaken at the ﬁrst prenatal visit.
Women with clinical characteristics con-
sistent with a high risk of GDM (marked
obesity, personal history of GDM, glyco-
suria, or a strong family history of diabe-
tes) should undergo glucose testing (see
below) as soon as feasible. If they are
found not to have GDM at that initial
screening, they should be retested be-
tween 24 and 28 weeks of gestation.
Women of average risk should have test-
ing undertaken at 24–28 weeks of
gestation.
A fasting plasma glucose level 126
mg/dl (7.0 mmol/l) or a casual plasma
glucose 200 mg/dl (11.1 mmol/l) meets
the threshold for the diagnosis of diabe-
tes. In the absence of unequivocal hyper-
Table 2—Criteria for the diagnosis of diabetes
1. FPG 126 mg/dl (7.0 mmol/l). Fasting is deﬁned as no caloric intake for at
least 8 h.*
OR
2. Symptoms of hyperglycemia and a casual plasma glucose 200 mg/dl (11.1
mmol/l). Casual is deﬁned as any time of day without regard to time since last
meal. The classic symptoms of hyperglycemia include polyuria, polydipsia, and
unexplained weight loss.
OR
3. 2-h plasma glucose 200 mg/dl (11.1 mmol/l) during an OGTT. The test
should be performed as described by the World Health Organization, using a
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in
water.*
*In the absence of unequivocal hyperglycemia, these criteria should be conﬁrmed by repeat testing on a
different day.
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conﬁrmed on a subsequent day. Conﬁr-
mation of the diagnosis precludes the
need for any glucose challenge. In the ab-
sence of this degree of hyperglycemia,
evaluation for GDM in women with aver-
ageorhigh-riskcharacteristicsshouldfol-
low one of two approaches.
One-step approach. Perform a diagnos-
tic OGTT without prior plasma or serum
glucosescreening.Theone-stepapproach
may be cost-effective in high-risk patients
or populations (e.g., some Native-
American groups).
Two-step approach. Perform an initial
screening by measuring the plasma or se-
rum glucose concentration 1 h after a
50-g oral glucose load (glucose challenge
test [GCT]) and perform a diagnostic
OGTTonthatsubsetofwomenexceeding
the glucose threshold value on the GCT.
When the two-step approach is used, a
glucose threshold value 140 mg/dl (7.8
mmol/l) identiﬁes 80% of women with
GDM,andtheyieldisfurtherincreasedto
90%byusingacutoffof130mg/dl(7.2
mmol/l).
With either approach, the diagnosis
of GDM is based on an OGTT. Diagnostic
criteria for the 100-g OGTT are derived
from the original work of O’Sullivan and
Mahan (4) modiﬁed by Carpenter and
Coustan (3) and are shown in the top of
Table 3. Alternatively, the diagnosis can
bemadeusinga75-gglucoseloadandthe
glucosethresholdvalueslistedforfasting,
1 h, and 2 h (Table 2, bottom); however,
this test is not as well validated as the
100-g OGTT.
References
1. The Expert Committee on the Diagnosis
and Classiﬁcation of Diabetes Mellitus:
Report of the Expert Committee on the
Diagnosis and Classiﬁcation of Diabetes
Mellitus. Diabetes Care 20:1183–1197,
1997
2. The Expert Committee on the Diagnosis
and Classiﬁcation of Diabetes Mellitus:
Follow-up report on the diagnosis of dia-
betes mellitus. Diabetes Care 26:3160–
3167, 2003
3. Carpenter MW, Coustan DR: Criteria for
screening tests for gestational diabetes.
Am J Obstet Gynecol 144:768–773, 1982
4. O’Sullivan JB, Mahan CM: Criteria for the
oral glucose tolerance test in pregnancy.
Diabetes 13:278, 1964
Table 3—Diagnosis of GDM with a 100-g or
75-g glucose load
mg/dl mmol/l
100-g glucose load
Fasting 95 5.3
1-h 180 10.0
2-h 155 8.6
3-h 140 7.8
75-g glucose load
Fasting 95 5.3
1-h 180 10.0
2-h 155 8.6
Two or more of the venous plasma concentrations
must be met or exceeded for a positive diagnosis.
The test should be done in the morning after an
overnightfastofbetween8and14handafteratleast
3daysofunrestricteddiet(150gcarbohydrateper
day) and unlimited physical activity. The subject
should remain seated and should not smoke
throughout the test.
Position Statement
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